A focused pipeline built around WASp modulation.
BIMINI is advancing first-in-class small molecule WASp modulators across oncology and autoimmune disease.
Our programmes combine a shared biological target with distinct mechanisms of action, allowing us to pursue different therapeutic opportunities from the same underlying biology.
Our candidates
A shared target for different indications.
BM series · WASp activation Acute myeloid leukemia Oncology
Evidence · Approximately 10 nM potency in selected responder cell lines, with in vivo proof of concept in an AML mouse model. / Current focus · Pharmacokinetic optimisation and further work in relapsed/refractory AML models.
BM series · WASp activation GCB-DLBCL Germinal centre B-cell diffuse large B-cell lymphoma
Evidence · Preclinical anti-tumour activity has been demonstrated in lymphoma models. / Current focus · Translational work to define the opportunity in relapsed/refractory GCB-DLBCL.
ZF-09 series · WASp inhibition Rheumatoid arthritis Autoimmune disease
Evidence · In vivo proof of concept in a collagen-induced arthritis model, with improvements in clinical score and paw volume versus control. / Current focus · Oral bioavailability and mechanism-of-action studies.
Oncology
Targeting cancer through WASp activation.
Our BM series consists of first-in-class small molecule WASp activators designed to increase actin polymerisation and induce apoptosis in WASp-dependent cancer cells.
BM series
Acute myeloid leukemia
Stage: Lead optimisation
The BM series consists of first-in-class small molecule WASp activators designed to increase actin polymerisation and induce apoptosis in WASp-dependent cancer cells.
Lead compounds have demonstrated approximately 10 nM potency in selected responder cell lines and strong anti-tumour activity in an orthotopic AML mouse model.
Current development is focused on further optimisation of pharmacokinetic properties and confirmation of activity in relapsed and refractory AML models.
BM series
Germinal centre B-cell
Diffuse large B-cell lymphoma
Stage: Preclinical translation
BIMINI is also evaluating the BM series in GCB-DLBCL, building on activity demonstrated across lymphoma models.
Preclinical translation is ongoing to further define the opportunity in relapsed and refractory disease.
Restoring immune balance through WASp inhibition.
The ZF-09 series is designed to inhibit WASp by increasing its degradation and reducing pathological immune cell activity.
ZF-09 series
Rheumatoid arthritis
Stage: Lead optimisation
The ZF-09 series is designed to inhibit WASp by increasing its degradation and reducing pathological immune cell activity.
ZF-09-123 has demonstrated in vivo proof of concept in a collagen-induced arthritis model, where treatment significantly improved clinical score and paw volume compared with control.
Lead optimisation is ongoing with a focus on improving oral bioavailability and further defining the mechanism of action in autoimmune disease.
Candidates
Advancing toward the clinic
BIMINI is progressing its lead programmes through preclinical development with the objective of moving its first programme toward IND-enabling development and first-in-human studies.
The company is developing its programmes with future pharmaceutical partnering in mind, supported by a growing package of pharmacology, safety, target engagement and translational data.